Q1 2026 ANI Pharmaceuticals Inc Earnings Call Transcript

May 8, 2026 / 12:00 PM GMT

Release Date Price: $81.86 (-2.44%)

Transcript 10-Q8-K

Key Points

Positve

ANI Pharmaceuticals Inc (ANIP) reported a 20% year-over-year increase in total net revenues for the first quarter, driven by strong performance in both rare disease and generics businesses.
The company raised its 2026 financial guidance for total revenue to a range of $1.08 billion to $1.14 billion and adjusted EBITDA to a range of $285 million to $300 million.
Clotrophin Gel, a lead rare disease asset, saw a 42% year-over-year increase in net revenues, with strong momentum in new patient starts and monthly volumes dispensed.
ANI Pharmaceuticals Inc (ANIP) entered into a licensing transaction with Harmony Biosciences, receiving a $15 million upfront license fee and potential for additional milestone payments and royalties.
The company launched six new generics products year-to-date and maintained its position as the number two player in overall CGT approvals.

Negative

Non-GAAP gross margin decreased by approximately 230 basis points from the prior-year period, primarily due to higher sales of royalty-bearing products.
Insurance re-verifications took longer to clear in the first quarter, impacting Cortrophin Gel's performance due to seasonality and weather-related physician office closures.
Non-GAAP selling, general, and administrative expenses increased by 12% due to initial marketing and recruitment expenses for organizational expansion.
The company faces ongoing Medicare market access challenges for its retina franchise, impacting Alluvian sales.
Despite strong first-quarter results, the company anticipates only modest sequential growth for Alluvian throughout the year.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ANIP.OQ - ANI Pharmaceuticals Inc
Q1 2026 ANI Pharmaceuticals Inc Earnings Call
May 08, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day, everyone, and welcome to today's ANI Pharmaceuticals, Inc. First Quarter 2026 Earnings Results Call.

Please note this call is being recorded.

After the speaker's prepared remarks, there will be a question-and-answer session. If you'd like to ask a question during this time, simply press *11 on your telephone keypad.

If you'd like to withdraw your question, please press *11 on your telephone keypad again.

It is now my pleasure to turn the conference over to Irina Koffler.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.